HomeCompareATXS vs QYLD

ATXS vs QYLD: Dividend Comparison 2026

ATXS yields 15.90% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATXS wins by $31.2K in total portfolio value
10 years
ATXS
ATXS
● Live price
15.90%
Share price
$12.58
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.6K
Annual income
$4,231.63
Full ATXS calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — ATXS vs QYLD

📍 ATXS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATXSQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATXS + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATXS pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATXS
Annual income on $10K today (after 15% tax)
$1,351.35/yr
After 10yr DRIP, annual income (after tax)
$3,596.89/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, QYLD beats the other by $1,213.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATXS + QYLD for your $10,000?

ATXS: 50%QYLD: 50%
100% QYLD50/50100% ATXS
Portfolio after 10yr
$41.0K
Annual income
$4,945.48/yr
Blended yield
12.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ATXS right now

ATXS
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Price Target
$13.00
+3.3% upside vs current
Range: $13.00 — $13.00
Altman Z
6.6
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATXS buys
0
QYLD buys
0
No recent congressional trades found for ATXS or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATXSQYLD
Forward yield15.90%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$56.6K$25.4K
Annual income after 10y$4,231.63$5,659.31
Total dividends collected$28.3K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ATXS vs QYLD ($10,000, DRIP)

YearATXS PortfolioATXS Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$12,290$1,589.83$10,352$1,192.36+$1.9KATXS
2$14,976$1,826.04$10,830$1,347.57+$4.1KATXS
3$18,104$2,079.61$11,460$1,539.07+$6.6KATXS
4$21,721$2,349.50$12,275$1,777.84+$9.4KATXS
5$25,876$2,634.46$13,323$2,078.95+$12.6KATXS
6$30,620$2,933.08$14,667$2,463.34+$16.0KATXS
7$36,007$3,243.80$16,396$2,960.57+$19.6KATXS
8$42,093$3,564.96$18,631$3,612.97+$23.5KATXS
9$48,934$3,894.82$21,548$4,482.15+$27.4KATXS
10$56,591$4,231.63$25,398$5,659.31+$31.2KATXS

ATXS vs QYLD: Complete Analysis 2026

ATXSStock

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Full ATXS Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this ATXS vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATXS vs SCHDATXS vs JEPIATXS vs OATXS vs KOATXS vs MAINATXS vs XYLDATXS vs JEPQATXS vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.